[1]熊依良.奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的疗效及安全性分析[J].医学信息,2018,31(19):142-144.[doi:10.3969/j.issn.1006-1959.2018.19.043]
　XIONG Yi-liang.Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the Treatment of Mild to Moderate Essential Hypertension[J].Medical Information,2018,31(19):142-144.[doi:10.3969/j.issn.1006-1959.2018.19.043]
点击复制

奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的疗效及安全性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年19期
页码:
142-144
栏目:
药物与临床
出版日期:
2018-10-01

文章信息/Info

Title:
Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the Treatment of Mild to Moderate Essential Hypertension
文章编号:
1006-1959（2018）19-0142-03
作者:
熊依良
江西省石城县人民医院医保科，江西 赣州 342700
Author(s):
XIONG Yi-liang
Department of Medical Insurance,People’s Hospital of Shicheng County,Ganzhou 342700,Jiangxi,China
关键词:
原发性高血压; 奥美沙坦酯氢氯噻嗪片; 氯沙坦钾氢氯噻嗪片; 安全性
Keywords:
Essential hypertension; Olmesartan Medoxomil and Hydrochlorothiazide Tablets; Losartan Potassium and Hydrochlorothiazide Tablets; Safety
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2018.19.043
文献标志码:
A
摘要:
目的 研究奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的临床疗效及安全性。方法 选取2017年1月~2018年1月来我院接受治疗的74例轻中度原发性高血压患者，随机分为观察组和对照组，每组37例。观察组接受奥美沙坦酯氢氯噻嗪片治疗，对照组接受氯沙坦钾氢氯噻嗪片治疗。治疗8周后，对比两组患者的临床疗效及用药安全性（肌酐、谷丙转氨酶水平、血小板计数及治疗期间不良反应发生情况）。结果 观察组临床总有效率为97.30%，优于对照组的75.68%，差异具有统计意义（P＜0.05）。治疗8周后，两组患者谷丙转氨酶、肌酐水平和血小板计数值均在正常范围内，观察组患者各项指标水平均优于对照组，即安全性高于对照组，差异具有统计学意义（P＜0.05）；治疗期间，观察组不良反应发生率与对照组相近（5.41% vs 2.70%），差异无统计学意义（P＞0.05）。结论 服用奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压，能有效提高临床疗效，用药安全性高。
Abstract:
Objective To study the clinical efficacy and safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the treatment of mild to moderate essential hypertension.Methods 74 patients with mild to moderate essential hypertension who were treated in our hospital from January 2017 to January 2018 were randomly divided into observation group and control group, with 37 cases in each group.The observation group received Olmesartan Medoxomil and Hydrochlorothiazide Tabletsand the control group received Losartan Potassium and Hydrochlorothiazide Tablets.After 8 weeks of treatment,the clinical efficacy and medication safety(creatinine,alanine aminotransferase level,platelet count,and adverse reactions during treatment)were compared between the two groups.Results The total effective rate of the observation group was 97.30%,which was better than that of the control group 75.68%,the difference was statistically significant(P<0.05).After 8 weeks of treatment,the levels of alanine aminotransferase,creatinine and platelet count in the two groups were within the normal range.The average level of the indicators in the observation group was better than that in the control group,that is,the safety was higher than that of the control group, and the difference was statistically significant(P<0.05);during the treatment period,the incidence of adverse reactions in the observation group was similar to that in the control group(5.41% vs 2.70%),the difference was not statistically significant(P>0.05).Conclusion The administration of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the treatment of mild to moderate essential hypertension can effectively improve the clinical efficacy and safety of medication.

参考文献/References:

[1]易春,赖晓菁,梁希武,等.奥美沙坦与坎地沙坦治疗轻、中度原发性高血压的疗效及安全性比较[J].中国心血管病研究,2013,11(3):190-193. [2]王力,谭虹,于晓峰.奥美沙坦治疗老年轻中度原发性高血压患者的效果及安全性研究[J].中国现代药物应用,2016,11(17):65-68. [3]李菁,秦廷莉,赵洛沙,等.国产与进口奥美沙坦酯对轻中度原发性高血压患者降压疗效与安全性的比较[J].中华老年心脑血管病杂志,2014,16(12):1275-1278. [4]张永州,安继红,吕维玲,等.奥美沙坦酯联合氨氯地平与奥美沙坦酯联合氢氯噻嗪治疗原发性高血压的对比[J].中国新药与临床杂志,2015,34(12):940-943. [5]于凤霞.奥美沙坦酯氢氯噻嗪治疗高血压的临床研究[J].现代药物与临床,2016,31(1):50-53. [6]秦黛.氯沙坦钾氢氯噻嗪片治疗原发性高血压52例疗效观察[J].中国伤残医学,2014,22(1):122-123.

相似文献/References:

[1]段淑婷,王义围,王兆鹏.高血压病合并糖调节受损患者血压变异性的相关研究[J].医学信息,2018,31(05):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
　DUAN Shu-ting,WANG Yi-wei,WANG Zhao-peng.Study on Blood Pressure Variability in Patients with Hypertension Complicated with Impaired Glucose Regulation[J].Medical Information,2018,31(19):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
[2]张 伟.动态血压监测不同剂型硝苯地平在原发性高血压患者中的治疗效果[J].医学信息,2022,35(10):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]
　ZHANG Wei.Effect of Different Dosage Forms of Nifedipine on Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension[J].Medical Information,2022,35(19):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]
[3]李信明,刘春梅,任正强,等.供需平衡视角下原发性高血压的病机与防治[J].医学信息,2018,31(19):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
　LI Xin-Ming,LIU Chun-Mei,REN Zheng-Qiang,et al.Pathogenesis and Prevention of Essential Hypertension from the Perspective of Supply and Demand Balance[J].Medical Information,2018,31(19):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
[4]穆大明.厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察[J].医学信息,2019,32(03):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
　MU Da-ming.Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension[J].Medical Information,2019,32(19):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
[5]郑艳芳,郭军霞,张永春.原发性高血压合并阵发性心房颤动的危险因素分析[J].医学信息,2021,34(22):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
　ZHENG Yan-fang,GUO Jun-xia,ZHANG Yong-chun.Risk Factors Analysis of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2021,34(19):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
[6]潘建鑫.高血压患者血小板/淋巴细胞比值与颈动脉粥样硬化的相关性分析[J].医学信息,2020,33(05):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
　Pan Jianxin.Correlation analysis of platelet/lymphocyte ratio and carotid atherosclerosisin patients with primary hypertension[J].Medical Information,2020,33(19):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
[7]谢祥红.AngⅡ、ET-1对高血压患者病情发生发展的影响[J].医学信息,2020,33(16):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
　XIE Xiang-hong.Effects of AngⅡ and ET-1 on the Occurrence and Development of Hypertension Patients[J].Medical Information,2020,33(19):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
[8]刘 柳,吕风华.原发性高血压患者脉压与左心室肥厚及射血分数保留的心衰的相关性[J].医学信息,2021,34(01):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
　LIU Liu,LYU Feng-hua.Correlation of Pulse Pressure with Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction in Patients with Essential Hypertension[J].Medical Information,2021,34(19):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
[9]魏 炜.奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果比较[J].医学信息,2021,34(14):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
　WEI Wei.Comparison of the Effects of Olmesartan Medoxomil and Candesartan Cilexetil in the Treatment of Essential Hypertension[J].Medical Information,2021,34(19):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
[10]谭碧峰,黄友良,凌 莎,等.基于有序Logistic回归模型的H型高血压疗效影响因素研究[J].医学信息,2022,35(05):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]
　TAN Bi-feng,HUANG You-liang,LING Sha,et al.Analysis of Influencing Factors on the Efficacy of H-type hypertension Based on Ordinal Logistic Regression Model[J].Medical Information,2022,35(19):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]

更新日期/Last Update: 2018-10-29